Kinase signal transduction inhibitors, such as trametinib and imatinib, block the ABL1, ERK–MAPK and PI3K–AKT–mTOR pathways, potentially preventing early virus invasion and resulting immune disorders [3, 70]. Here, AKT1 is linked to immune system disorder.